<DOC>
	<DOCNO>NCT01124630</DOCNO>
	<brief_summary>Treatment CS-1008 combination FOLFIRI ( irinotecan , leucovorin , 5-fluorouracil [ 5-FU ] ) subject metastatic colorectal cancer ( CRC ) fail first-line treatment irinotecan-based .</brief_summary>
	<brief_title>Study CS-1008 Combination With FOLFIRI Patients Who Have Failed Other Treatments</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm , metastatic CRC progress firstline standard therapy irinotecanbased . At least 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 . Adequate organ bone marrow function evidence : Hemoglobin &gt; = 9 g/dL White blood cell count ( WBC ) &gt; = 3.0 x 109/L Absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L Platelet count &gt; = 100 x 109/L Serum creatinine &lt; upper limit normal ( ULN ) AST alkaline phosphatase = &lt; 2.5 x ULN without liver metastasis = &lt; 5.0 x ULN liver metastasis Total bilirubin = &lt; ULN Male female subject reproductive potential must willing consent use effective contraception treatment 3 month end treatment . Female subject childbearing potential must negative pregnancy test ( serum urine ) result within 8 day start study treatment . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IRBapproved ICF performance studyspecific procedure test . At study center locate US , subject must also sign HIPAA authorization . KRAS Mutant Anticipation need major surgical procedure radiotherapy ( RT ) study . Treatment chemotherapy , hormonal therapy , RT , minor surgery , investigational agent within 4 week study enrollment . Treatment nitrosoureas , mitomycin C , immunotherapy , biological therapy , major surgery within 6 week study enrollment . Firstline therapy CRC irinotecanbased . History follow condition within 6 month study enrollment : Myocardial infarction ; Severe/unstable angina pectoris ; Coronary/peripheral artery bypass graft ; New York Heart Association ( NYHA ) class III IV congestive heart failure ; Cerebrovascular accident transient ischemic attack ; Pulmonary embolism clinically significant thromboembolic event ; Clinically significant pulmonary disease ( eg , severe chronic obstructive pulmonary disease asthma ) . Clinically active brain metastasis ( ie , untreated , still require therapy steroid RT , progression within 4 week completion RT ) ; uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis . History malignancy CRC , unless expectation malignancy cure , tumorspecific treatment malignancy administer within previous 5 year . Clinically significant active infection require antibiotic therapy Human Immunodeficiency Virus ( HIV ) positive subject receive antiretroviral therapy . Previous treatment CS1008 , agonistic DRSantibodies , TRAIL agonists . If female , pregnant breastfeeding . Known history hypersensitivity reaction component CS1008 , irinotecan , leucovorin , 5FU formulation . Serious intercurrent medical psychiatric illness condition opinion Investigator would impair ability give inform consent unacceptably reduce protocol compliance safety study treatment . Must know homozygous UGT1A1*28 allele , increase risk neutropenia follow irinotecan treatment . Kras allele status must wild type . Dihydropyrimidine dehydrogenase ( DPD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>